National and Kapodistrian University of Athens
Ανοσογονικότητα, ανοσολογική μνήμη και συσχέτιση με υποτροπές του 13-δυναμου συζευγμένου πνευμονιοκοκκικού εμβολίου (PCV13) σε παιδιά με ευαίσθητο και ανθεκτικό στα στεροειδή Ιδιοπαθές Νεφρωσικό Σύνδρομο (Idiopathic Nephrotic Syndrome-INS)
Abstract
dc:descriptionBackground: Immunization with the 13-valent Pneumococcal Conjugate Vaccine (PCV13) is recommended in children with idiopathic nephrotic syndrome (INS), while reduced immunogenicity and duration of protection have been documented in these children, particularly those undergoing immunomodulatory treatment. We evaluated the safety of a single anamnestic immunization with the PCV13 in children with INS in remission and the effect of different immunomodulatory treatments on PCV13immunogenicity and induction of immunological memory. Materials and Methods: Safety was assessed through proteinuria evaluation following PCV13 booster administration and the kinetics of interleukin (IL)-5 and IL-13 levels, as biomarkers of INS activity, while all INS relapses were recorded for the 6 months following immunization. Immunogenicity and induction of immunological memory were assessed in patients and healthy controls by monitoring the kinetics of antigen-specific antibody titers for pneumococcal serotypes, at 4 weeks and 12 months, and pneumococcal serotype (PS)-specific B-cells, B Memory Cells (BMCs) and Ig isotypes witched BMCs (sIg BMCs), respectively.Results:PCV13 did not affect the individual relapse risk. Serum IL-5 changes were similar among patients with and without relapses and between INS patients and controls, during the follow-up period. Following booster immunization, PS-specific antibody titers showed a significant increase in all treatment groups and healthy controls. However, children receiving immunomodulatory treatments displayed significantly lower levels of PS-specific antibodies for 3/8 vaccine serotypes tested at both timepoints. PS-specific B-cell, BMC and sIg BMC counts significantly increased in healthy controls and patients with INS receiving corticosteroids; in contrast, patients receiving immunomodulatory treatment with cyclosporin A did not exhibit a significant increase following booster immunization.Conclusions:PCV13 booster was safe, well tolerated and immunogenic in children with INSin remission. The establishment of antigen-specific immunological memory is highly associated with the treatment regime used for INS, with immunomodulatory treatments resulting in impaired PS-specific B cell responses that could lead to the accelerated waning of antibody titers observed in these patients.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kitsou, Konstantina
- Κίτσου, Κωνσταντίνα
Subjects
dc:subject × 13Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/58725